Imunon Inc - Company Profile

Powered by

All the data and insights you need on Imunon Inc in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Imunon Inc Strategy Report

  • Understand Imunon Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Imunon Inc: Overview

Select Item

Imunon Inc (Imunon), formerly Celsion Corp is a clinical-stage oncology company with a focus on developing a portfolio of new cancer treatments, including directed chemotherapies, RNA and DNA based therapies and immunotherapies. The company develops drugs using its three platform technologies including Lysolipid Thermally Sensitive Liposomes (LTSL), TheraPlas and TheraSilence. Its lead product candidate ThermoDox is a proprietary form of doxorubicin based LTSL technology in Phase III clinical trial for the treatment of primary liver cancer. It is also developing a pipeline of targeted therapeutic agents for cancer. Imunon is headquartered in Lawrenceville, New Jersey, the US.

 Gain a 360-degree view of Imunon Inc and make more informed decisions for your business Gain a 360-degree view of Imunon Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 997 Lenox Dr Ste 100, Lawrenceville, New Jersey, 08648
Website imunon.com
Telephone 1 609 8969100
No of Employees 33
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange IMNN (NASD)
EPS XYZ
Net Income (2022) XYZ 45.6% (2022 vs 2021)
Market Cap* $10.6M
Net Profit Margin (2021) XYZ -72.8% (2022 vs 2021)
   
* As of and is in US$
View Imunon Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Imunon Inc premium industry data and analytics

40+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Imunon Inc’s relevant decision makers and contact details.

20+

Clinical Trials

Determine Imunon Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Catalyst Calendar

Proactively evaluate Imunon Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

10+

Pipeline Drugs

Identify which of Imunon Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

4

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products Brands
Technology: TheraPlas
TheraSilence TheraSilence
TheraPlas ThermoDox
XYZ
XYZ
XYZ
Understand Imunon Inc portfolio and identify potential areas for collaboration Understand Imunon Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Corporate Changes/Expansions In June, the company inaugurated its new materials production facility, located on the Huntsville campus of the HudsonAlpha Institute for Biotechnology.
2023 Contracts/Agreements In January, the company entered into a research agreement with The Wistar Institute’s Vaccine & Immunotherapy Center to research Imunon’s placcine vaccine platform.
2022 Contracts/Agreements In November, the company entered into an agreement with Acuitas Therapeutics to evaluate the combination of PLACCINE nucleic acid vaccine constructs formulated with Acuitas’ proprietary lipid delivery technology.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Imunon Inc Merck & Co Inc Bristol-Myers Squibb Co Amgen Inc Clovis Oncology Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Lawrenceville Kenilworth Princeton Thousand Oaks Boulder
State/Province New Jersey New Jersey New Jersey California Colorado
No. of Employees 33 72,000 34,100 26,700 -
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Michael H. Tardugno Chairman; Chief Executive Officer Executive Board 2024 72
Jeffrey W. Church Executive Vice President; Chief Financial Officer; Corporate Secretary Senior Management 2011 66
Sebastien Hazard, M.D. Chief Medical Officer Senior Management 2023 -
Khursheed Anwer Ph.D. Chief Scientific Officer; Executive Vice President Senior Management 2014 63
James E. Dentzer Director Non Executive Board 2022 56
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Imunon Inc key executives to enhance your sales strategy Gain insight into Imunon Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward